Cardiology, Department of Experimental and Applied Medicine, University and Civil Hospital of Brescia, c/o Spedali Civili, Piazza Spedali Civili 1, 25123 Brescia, Italy.
Clin Res Cardiol. 2012 Aug;101(8):663-72. doi: 10.1007/s00392-012-0441-5. Epub 2012 Mar 10.
Myocardial injury during an episode of acute heart failure (AHF) may be important for patents' outcome. We hypothesised that an increase of cardiac troponin levels (cTnT) during hospitalisation, in patients with undetectable levels on admission (cTnT release), may be a more specific marker of myocardial damage. With this aim, we assessed the clinical and prognostic significance of high serum cTnT levels at the time of admission and that of cTnT release in 198 consecutive patients admitted for AHF and with no signs of acute coronary syndrome.
cTnT levels were serially measured at the time of admission, and after 6 and 12 h, in 198 consecutive patients admitted for AHF and with no signs of acute coronary syndrome. cTnT was detectable (>0.01 ng/mL) in 102 patients (52 %) and positive for myocardial necrosis (>0.03 ng/mL) in 78 patients (39 %). Negative cTnT at the time of admission became positive at 6 and/or 12 h in 36 (18 %) patients. Patients with increased cTnT levels were more likely to have coronary artery disease, hypertension, diabetes, and renal dysfunction. During a median follow-up duration of 247 days (IQR 96-480 days), the detection of increased cTnT levels was associated with a higher rate of all-cause deaths and, for cTnT release, all-cause death and cardiovascular rehospitalisation rate. CTnT release was an independent predictor of all-cause death and cardiovascular rehospitalisation, along with glomerular filtration rate, and the administration of inotropic agents during the initial hospitalisation.
Increased cTnT levels are a frequent finding in patients with AHF. They are more likely to occur in patients with comorbidities and are associated with poorer outcomes. cTnT release is an independent predictor of poorer outcomes.
急性心力衰竭(AHF)发作期间的心肌损伤可能对患者的预后很重要。我们假设,入院时检测不出心肌肌钙蛋白 T 水平(cTnT)(cTnT 释放)的患者,其入院期间 cTnT 水平升高可能是心肌损伤的更特异性标志物。为此,我们评估了 198 例因 AHF 入院且无急性冠状动脉综合征迹象的患者入院时高血清 cTnT 水平和 cTnT 释放的临床和预后意义。
连续测量了 198 例因 AHF 入院且无急性冠状动脉综合征迹象的患者入院时、6 小时和 12 小时的 cTnT 水平。102 例患者(52%)可检测到 cTnT(>0.01ng/ml),78 例患者(39%) cTnT 呈阳性(>0.03ng/ml)。入院时 cTnT 阴性的患者中有 36 例(18%)在 6 小时和/或 12 小时时转为阳性。cTnT 水平升高的患者更可能患有冠状动脉疾病、高血压、糖尿病和肾功能障碍。在中位随访 247 天(IQR 96-480 天)期间,cTnT 水平升高与全因死亡发生率较高相关,而对于 cTnT 释放,全因死亡和心血管再入院率较高。cTnT 释放是全因死亡和心血管再入院的独立预测因子,与肾小球滤过率和初始住院期间使用正性肌力药物有关。
cTnT 水平升高是 AHF 患者的常见发现。它们更可能发生在合并症患者中,与较差的结局相关。cTnT 释放是预后不良的独立预测因子。